Sorry, you need to enable JavaScript to visit this website.

What is FASPRO®| DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)


DARZALEX FASPRO® is a prescription medicine used to treat adults with multiple myeloma.



DARZALEX FASPRO® is the subcutaneous (injected under the skin) formulation of daratumumab, used to treat:

  • Newly diagnosed patients who can or cannot receive a transplant
  • Patients who have had one or more other treatments for multiple myeloma

It is given by your healthcare provider under the skin in the stomach area (abdomen) and takes about 3 to 5 minutes


Prescribed alone or in combination with one or more treatments

See the Indications for DARZALEX FASPRO® below on this web page.

Explore the clinical experience of DARZALEX FASPRO®

How DARZALEX FASPRO® works to fight multiple myeloma

DARZALEX FASPRO® is made up of 2 main components

Daratumumab (pronounced da-ra-tu-mu-mab)

Daratumumab is the ingredient that treats
multiple myeloma

Hyaluronidase (pronounced hy-a-lur-on-i-dase)

Hyaluronidase helps daratumumab to be injected into the skin and absorbed into the body

Daratumumab in action

Teal and purple multiple myeloma cell

Multiple myeloma cells, like other types of cancer, can go unrecognized by your body, which allows the cells to grow.

Daratumumab attaching to the surface of a multiple myeloma cell

Daratumumab attaches itself to the CD38 protein on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.

Free-floating daratumumab and destroyed pieces of a multiple myeloma cell

Daratumumab directly kills multiple myeloma cells and/or allows your immune system to identify and destroy them. Because of the way daratumumab works, it may also affect normal cells.


Newly diagnosed

Transplant ineligible*

DRd: in combination with lenalidomide and dexamethasone

DVMP: in combination with bortezomib, melphalan, and prednisone

Transplant eligible*

DVTd: in combination with bortezomib, thalidomide, and dexamethasone

Previously treated

After ≥1 prior medicine

DRd: in combination with lenalidomide and dexamethasone

DVd: in combination with bortezomib and dexamethasone

DPd: in combination with pomalidomide and dexamethasone and previously treated with lenalidomide and a PI

After ≥3 prior medicines

Alone: previously treated with a PI and an immunomodulatory agent, or patients who did not respond to a PI and an immunomodulatory agent

*Transplant ineligible refers to when a person with multiple myeloma cannot receive a stem cell transplant, whereas transplant eligible means that a person with multiple myeloma can receive a stem cell transplant.

DRd=DARZALEX FASPRO® (D) + lenalidomide (R) + dexamethasone (d); DVd=DARZALEX FASPRO® (D) + bortezomib (V) + dexamethasone (d); DVMP=DARZALEX FASPRO® (D) + bortezomib (V) + melphalan (M) + prednisone (P); DVTd=DARZALEX FASPRO® (D) + bortezomib (V) + thalidomide (T) + dexamethasone (d); PI=proteasome inhibitor.

treatment is given